Allergan PLC. (NYSE: AGN) and Parnell Pharmaceuticals Holdings (NASDAQ:PARN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
This is a summary of recent ratings and recommmendations for Allergan PLC. and Parnell Pharmaceuticals Holdings, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Parnell Pharmaceuticals Holdings||0||0||0||0||N/A|
Allergan PLC. presently has a consensus price target of $276.82, indicating a potential upside of 25.66%. Given Allergan PLC.’s higher probable upside, equities analysts clearly believe Allergan PLC. is more favorable than Parnell Pharmaceuticals Holdings.
Earnings & Valuation
This table compares Allergan PLC. and Parnell Pharmaceuticals Holdings’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Allergan PLC.||$15.07 billion||4.89||$6.15 billion||$28.15||7.83|
|Parnell Pharmaceuticals Holdings||N/A||N/A||N/A||N/A||N/A|
Allergan PLC. has higher revenue and earnings than Parnell Pharmaceuticals Holdings.
Insider & Institutional Ownership
82.1% of Allergan PLC. shares are owned by institutional investors. Comparatively, 16.9% of Parnell Pharmaceuticals Holdings shares are owned by institutional investors. 0.4% of Allergan PLC. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Allergan PLC. pays an annual dividend of $2.80 per share and has a dividend yield of 1.3%. Parnell Pharmaceuticals Holdings does not pay a dividend. Allergan PLC. pays out 9.9% of its earnings in the form of a dividend.
This table compares Allergan PLC. and Parnell Pharmaceuticals Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Parnell Pharmaceuticals Holdings||-130.46%||-83.86%||-43.24%|
Risk and Volatility
Allergan PLC. has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Parnell Pharmaceuticals Holdings has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500.
Allergan PLC. beats Parnell Pharmaceuticals Holdings on 10 of the 11 factors compared between the two stocks.
Allergan PLC. Company Profile
Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
Parnell Pharmaceuticals Holdings Company Profile
Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.